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Abstract
Background: Drug-eluting stent (DES) -induced coronary vasospasm is a well known phenomenon after stent
implantation; however, the extent of this risk is still unknown. We report a case in which DES-induced severe
coronary vasospasm was clinically suspected as a cause of subacute stent thrombosis (ST).
Case presentation: A 67-year-old man came to our hospital due to chest pain with mild exercise. He was diagnosed
with effort angina by coronary angiography and underwent DES implantation in the mid-left ascending artery (LAD)
after the administration of dual anti-platelet therapy. The procedure was uneventful, but his symptoms changed from
effort angina to rest angina after stenting. Five days after the procedure, subacute ST occurred, requiring aspiration
thrombectomy and balloon angioplasty. Thereafter, he continued to report early morning chest discomfort. We
performed a spasm provocation test to evaluate the coronary vasomotor response; it revealed severe stent-edge
spasm in the left main trunk to the LAD, except for the stented lesion, and total occlusion of the left circumflex artery.
Conclusions: To our knowledge, the present case is the first report describing in-stent thrombosis secondary to stent-
edge spasm. This case describes the potential hazard of DES-induced coronary vasospasm. Although there are several
overlapping risk factors for ST development, we consider that stent-edge spasm also plays an important role in ST
development. Therefore, we should monitor new-onset rest angina after stent implantation and carefully assess
DES-induced coronary vasospasm.
Keywords: Percutaneous coronary intervention, Effort angina, Vasospastic angina, Stent-edge spasm, In-stent
thrombosis
Background
Although drug-eluting stents (DES) reduce restenosis after
percutaneous coronary intervention (PCI) more effectively
than bare-metal stents (BMS), there are a variety of DES-
related complications, such as coronary artery vasospasm.
Some reports have suggested that endothelial dysfunction
and enhanced vascular smooth muscle contractility with
the involvement of the Rho-kinase pathway play an im-
portant role in the pathogenesis of DES-induced coronary
vasospasm [1, 2]. Coronary vasospasm increases the risk
of life-threatening cardiovascular events. An inability to
administer adjunctive medical treatment for DES-induced
coronary vasospasm after stent implantation promotes the
coagulation system and thrombus formation, which may
result in acute myocardial infarction [3, 4]. Here, we
present a case in which DES-induced severe coronary
vasospasm was clinically suspected as a cause of subacute
stent thrombosis (ST).
Case presentation
A 67-year-old man presented with effort angina for one
month. His coronary risk factors were current smoking
and dyslipidemia, and his only regular medication was
rosuvastatin. There was no significant past medical
history. His baseline electrocardiogram (ECG) and echo-
cardiography were normal, but coronary angiography
(CAG) revealed intermediate stenosis in the left ascending
artery (LAD) and left circumflex artery (LCx). We
performed fractional flow reserve in the LAD and LCx;
the results were 0.77 and 0.79, respectively (Fig. 1). We
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planned elective PCI to the LAD for effort angina. After
starting dual anti-platelet therapy (DAPT) with 100 mg/day
aspirin and 75 mg/day clopidogrel, successful angioplasty of
the mid-LAD was performed. An everolimus-eluting stent
(3.25 mm in diameter, 33 mm in length) was deployed with
high pressure balloon (3.5/10 mm) post-dilatation (Fig. 2a
and 2b). The final angiogram indicated good blood flow
and the intravascular ultrasound indicated that the stent
was well-expanded and there was no incomplete apposition
(Fig. 2c-f). However, the patient reported new-onset chest
discomfort at rest the next morning. The symptom resolved
after a few minutes with no significant ECG changes and
he was discharged. However, 5 days after the PCI, he was
transported to our hospital by ambulance due to crushing
chest pain while drinking. On admission, his ECG revealed
ST-segment elevation in the precordial leads. In the emer-
gency room, ECG monitoring detected ventricular fibrilla-
tion, and a counter-shock was successfully delivered. He
then underwent emergent CAG, which revealed thrombotic
total occlusion of the proximal LAD (Fig. 3a and 3b). We
diagnosed subacute ST and performed PCI. Aspiration
thrombectomy and balloon angioplasty with a 3.25/15 mm
balloon were performed (Fig. 3c and 3d) and TIMI-3 flow
was obtained (Fig. 3e and 3f). After these procedures, he
Fig. 1 Pre-intervention coronary angiography. The left coronary artery showed intermediate stenosis in the proximal left ascending artery and left
circumflex artery. Fractional flow reserve was 0.77 and 0.79 in the left ascending artery and left circumflex artery, respectively. AP anterior-posterior,
RAO right anterior oblique
Fig. 2 Elective percutaneous coronary intervention to the left ascending artery (a and b) and intravascular ultrasound findings (c-f). a Implantation
of an everolimus-eluting stent (3.25 mm in diameter, 33 mm in length). b Final angiogram after post-dilatation, indicating good blood flow. c-f
Intravascular ultrasound findings of the implanted everolimus-eluting stent (c proximal part of the stent, d part of first diagonal branch, e part of
second diagonal branch, f distal part of the stent) indicating that the stent was well-expanded and without incomplete apposition
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was admitted to the intensive care unit, where we
confirmed the resolution of his critical status. There were
no major complications and his general condition was
improving, but he subsequently reported frequent chest
discomfort, especially during the night and in the early
morning. Although no significant ECG changes were
observed, we performed follow-up CAG and a spasm
provocation test with ergonovine to evaluate the coronary
vasomotor response 2 weeks after the initial PCI. The
baseline angiography revealed no significant findings (Fig. 4a
and 4b). However, intracoronary infusion of 40 μg of
ergonovine into the left coronary artery provoked severe
vasospasm from the left main trunk (LMT) to the LAD, ex-
cept for the stented lesion, and total occlusion was detected
in the LCx (Fig. 4c and 4d). He indicated the chest discom-
fort was the same as usual. An isosorbide dinitrate injection
improved both the vasospasm and the discomfort (Fig. 4e
and 4f). His condition was diagnosed as coronary vasospas-
tic angina (VSA); treatment with calcium channel blockers
and nicorandil resolved his symptoms. We evaluated his
cytochrome P450 2C19 (CYP2C19) genotype and deter-
mined he had a CYP2C19 polymorphism and was therefore
a poor metabolizer of clopidogrel. Thus, we replaced the
75 mg/day clopidogrel with 3.75 mg/day prasugrel. His
post-discharge clinical course was uneventful.
Conclusions
We experienced a case of DES-induced severe coronary
vasospasm, which may have contributed to the development
of subacute ST. Although single stenting of the LMT
showed a comparable clinical outcome compared to two-
stent strategy [5], in this case, the intravascular ultrasound
on initial PCI showed no significant stenosis in the LMT
and we deployed DES only in the LAD lesion. In addition,
ECG changes when stent-edge spasm was provoked after in-
jection of ergonovine showed axis deviation to the left. This
might indicate ischemia of the ventricular septum induced
by vasospasm occurring in the first major septal branch.
This case is clinically important because it describes the
potential hazard of stent-edge spasm after stent implant-
ation. The patient’s clinical course provides the following
two important clinical suggestions. First, that DES
implantation for effort angina can induce new-onset
stent-edge spasm, and second, stent-edge spasm may have
an important role in the development of subacute ST.
The first clinical suggestion is that DES implantation for
effort angina can induce new-onset stent-edge spasm. A
recent study showed that endothelial dysfunction and en-
hanced vascular smooth muscle contractility with the in-
volvement of the Rho-kinase pathway play an important
role in the pathogenesis of DES-induced coronary vaso-
spasm [1, 2]. Coronary vasoconstrictive responses are en-
hanced at the edges of coronary segments implanted with
DES compared with BMS. The incidence of provoked
spasm is not different between patients with and without
VSA before stenting [6]; therefore, it is important to be
concerned about the occurrence of new stent-edge spasm
in patients both with and without VSA. It is possible that
repeated, broad, strong, and long stent-edge spasm results
in new cardiac events, and death was reported in some
patients with severe multivessel, non-intervention-related
vascular spasm after DES implantation [7, 8]; adjunctive
medical treatment is critical for these patients. Long-term
administration of vasodilating drugs, such as calcium
Fig. 3 Emergent coronary angiography and percutaneous coronary intervention for subacute stent thrombosis. a and b Total occlusion of the
proximal part of the stent with thrombus. c and d Aspiration thrombectomy and balloon angioplasty (high-pressure balloon, 3.25/15 mm) were
performed. e and f Final coronary angiogram, indicating TIMI grade 3 flow. POBA plain old balloon angioplasty
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channel blockers and nitrates are useful for inhibiting cor-
onary vasospasm. Among four major calcium channel
blockers (benidipine, amlodipine, nifedipine, diltiazem)
that effectively suppress VSA, benidipine has shown
significantly more beneficial prognostic effects [9].
The second clinical suggestion is that stent-edge spasm
may have an important role in the development of subacute
ST. There are two possible reasons for this phenomenon.
The first is that coronary vasospasm promotes coagulation
and may lead to thrombus formation. Some studies focused
on the relationship between coronary vasospasm and
thrombus formation have observed accelerated
platelet and coagulation activities induced by coronary
artery spasms [3, 10]. Platelet aggregation in the
coronary circulation causes coronary thrombus forma-
tion, which may result in acute myocardial infarction
[4]. Several cases in which coronary vasospasm led to
coronary thrombosis and myocardial infarction have
also been reported [11, 12], supporting a potential
mechanism underlying the phenomenon of the stent-
edge spasm-related subacute ST in this patient. The
second possible reason for the phenomenon of sub-
acute ST secondary to stent-edge spasm is that this
patient had few subacute ST risk factors except for
the CYP2C19 polymorphism and the stent-edge
spasm. CYP2C19 polymorphisms have been associated
with weaker antiplatelet responses to clopidogrel, and
nonresponsiveness to clopidogrel is an independent
predictor of ST [13]. However, CYP2C19 polymorphisms
are frequent, especially in Japanese individuals, and the in-
cidence is estimated about 20–25% of Japanese population
[14]. Therefore, multiple overlapping risk factors are
required for the development of ST, even in patients that
are poor metabolizers of clopidogrel. Several studies have
evaluated the potential predictors of acute and subacute
ST. Multiple risk factors related to devices, patients, le-
sions, and procedure have been suggested in the develop-
ment of ST [15, 16]. Although this patient had a
CYP2C19 polymorphism, he had no other significant risk
factors for the development of subacute ST. Device-
related factors (e.g., stent material and design) were not a
problem. Regarding patient and lesion-related factors, this
patient did not have acute coronary syndrome, old age,
diabetes, or low left ventricular ejection fraction and the
target lesion was non-complex with simple characteristics.
Concerning procedure-related factors, the deployed stent
had no morphometric (underexpansion or asymmetry) or
morphologic (dissection, incomplete apposition, or tissue
protrusion) abnormalities. Therefore, another mechanism
beyond the above risk factors must have played a role in
ST development in this case. It is possible that the pa-
tient’s platelet function was not adequately reduced des-
pite the standard post-stent DAPT administration
(100 mg/day aspirin and 75 mg/day clopidogrel) before
PCI. In addition, the stent-edge spasm likely promoted the
coagulation system and thrombus formation to increase
the risk of ST.
Unfortunately, we lacked a baseline spasm provocation
test before DES implantation and it is unknown whether
coronary vasospasm was already present or not. However,
the result of the fractional flow reserve evaluation showed
myocardial ischemia and the patient’s symptoms also
obviously changed from typical exertional chest pain to
chest discomfort at rest after stenting. The clinical course
Fig. 4 The spasm provocation test. a and b Baseline coronary angiography. c and d Intracoronary infusion of ergonovine induced a severe spasm
in the left coronary artery, except for the stented lesion; the left circumflex artery was occluded. e and f Intracoronary infusion of isosorbide dinitrate
completely resolved the coronary vasospasm. EES everolimus-eluting stent, Erg ergonovine, ISDN isosorbide dinitrate
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indicated that his coronary vasomotor response was not
clinically problematic before stenting, even if he already
had coronary vasospasm. Therefore, we believe that coron-
ary vasospasm became apparent after DES implantation
and that stent-edge spasm should have been treated with
antivasoconstrictive drugs to control and prevent the
occurrence of subacute ST.
This case is clinically important because it describes
the potential hazard of DES-induced coronary vaso-
spasm, which may have caused subacute ST. Although
various risk factors overlap to contribute to the develop-
ment of ST, we believe stent-edge spasm also has an im-
portant role in ST development. Therefore, we should
monitor new-onset rest angina after stent implantation
and carefully assess DES-induced coronary vasospasm.
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